Cytokinetics Inc (CYTK)
51.48
-0.34
(-0.66%)
USD |
NASDAQ |
Nov 04, 16:00
51.50
+0.02
(+0.04%)
After-Hours: 20:00
Cytokinetics Enterprise Value: 5.655B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
November 04, 2024 | 5.655B |
November 01, 2024 | 5.695B |
October 31, 2024 | 5.599B |
October 30, 2024 | 5.635B |
October 29, 2024 | 5.659B |
October 28, 2024 | 5.747B |
October 25, 2024 | 5.636B |
October 24, 2024 | 5.764B |
October 23, 2024 | 5.839B |
October 22, 2024 | 6.062B |
October 21, 2024 | 5.929B |
October 18, 2024 | 6.066B |
October 17, 2024 | 6.014B |
October 16, 2024 | 6.102B |
October 15, 2024 | 6.114B |
October 14, 2024 | 6.011B |
October 11, 2024 | 6.055B |
October 10, 2024 | 5.852B |
October 09, 2024 | 5.999B |
October 08, 2024 | 5.991B |
October 07, 2024 | 6.125B |
October 04, 2024 | 6.267B |
October 03, 2024 | 6.153B |
October 02, 2024 | 5.788B |
October 01, 2024 | 5.787B |
Date | Value |
---|---|
September 30, 2024 | 5.811B |
September 27, 2024 | 5.756B |
September 26, 2024 | 5.791B |
September 25, 2024 | 5.796B |
September 24, 2024 | 5.794B |
September 23, 2024 | 5.727B |
September 20, 2024 | 5.925B |
September 19, 2024 | 6.140B |
September 18, 2024 | 6.180B |
September 17, 2024 | 6.206B |
September 16, 2024 | 6.275B |
September 13, 2024 | 6.173B |
September 12, 2024 | 5.959B |
September 11, 2024 | 5.925B |
September 10, 2024 | 5.969B |
September 09, 2024 | 6.167B |
September 06, 2024 | 5.962B |
September 05, 2024 | 6.179B |
September 04, 2024 | 6.057B |
September 03, 2024 | 6.018B |
August 30, 2024 | 6.314B |
August 29, 2024 | 6.351B |
August 28, 2024 | 6.132B |
August 27, 2024 | 6.169B |
August 26, 2024 | 6.313B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
349.05M
Minimum
Nov 12 2019
10.99B
Maximum
Jan 08 2024
3.140B
Average
3.004B
Median
May 31 2022
Enterprise Value Benchmarks
Alnylam Pharmaceuticals Inc | 33.06B |
Biomarin Pharmaceutical Inc | 12.24B |
Catalyst Pharmaceuticals Inc | 2.205B |
Sarepta Therapeutics Inc | 11.50B |
Ocugen Inc | 260.88M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -143.32M |
Revenue (Quarterly) | 0.249M |
Total Expenses (Quarterly) | 130.42M |
EPS Diluted (Quarterly) | -1.31 |
Gross Profit Margin (Quarterly) | -31.87K% |
Profit Margin (Quarterly) | -57.56K% |
Earnings Yield | -10.43% |
Normalized Earnings Yield | -10.42 |